Giacomo Miserocchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9643997/publications.pdf

Version: 2024-02-01

623734 610901 25 637 14 24 citations g-index h-index papers 25 25 25 882 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. International Journal of Molecular Sciences, 2016, 17, 1375.	4.1	78
2	Management and potentialities of primary cancer cultures in preclinical and translational studies. Journal of Translational Medicine, 2017, 15, 229.	4.4	75
3	Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. OncoTargets and Therapy, 2016, Volume 9, 6233-6246.	2.0	65
4	Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. Scientific Reports, 2021, 11, 5107.	3.3	37
5	The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patientâ€derived primary culture case series in tridimensional and zebrafish models. Journal of Experimental and Clinical Cancer Research, 2021, 40, 165.	8.6	35
6	Myxofibrosarcoma primary cultures: molecular and pharmacological profile. Therapeutic Advances in Medical Oncology, 2017, 9, 755-767.	3.2	31
7	Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. International Journal of Molecular Sciences, 2017, 18, 2662.	4.1	31
8	A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences. Biomedicines, 2022, 10, 372.	3.2	29
9	The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. International Journal of Molecular Sciences, 2016, 17, 1827.	4.1	27
10	Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. OncoTargets and Therapy, 2017, Volume 10, 1155-1164.	2.0	27
11	Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. International Journal of Molecular Sciences, 2017, 18, 1655.	4.1	23
12	Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210939.	3.2	22
13	Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma. Molecules, 2016, 21, 1662.	3.8	21
14	Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas. Cancer Biology and Medicine, 2021, 18, 502-516.	3.0	21
15	Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas. International Journal of Molecular Sciences, 2021, 22, 11564.	4.1	21
16	Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy. Frontiers in Oncology, 2021, 11, 740676.	2.8	17
17	Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line. Cells, 2018, 7, 186.	4.1	12
18	Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches. Journal of Personalized Medicine, 2022, 12, 854.	2.5	12

#	ARTICLE	IF	CITATION
19	Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biology Open, 2016, 6, 133-140.	1.2	11
20	Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma. Journal of Visualized Experiments, $2018, , .$	0.3	10
21	Lineageâ€specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture. Molecular Oncology, 2022, 16, 921-939.	4.6	10
22	Identification of a novel RAB3IPâ€HMGA2 fusion transcript in an adult head and neck rhabdomyosarcoma. Oral Diseases, 2022, 28, 2052-2054.	3.0	7
23	mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model. Journal of Bone Oncology, 2019, 16, 100227.	2.4	6
24	Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines. Journal of Visualized Experiments, 2017, , .	0.3	5
25	BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center "Real-Life―Experience (BOHEME Study). Journal of Clinical Medicine, 2019, 8, 1894.	2.4	4